Viewing Study NCT01289457

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:59 PM
Ignite Modification Date: 2026-01-04 @ 5:07 PM
Study NCT ID: NCT01289457
Status: COMPLETED
Last Update Posted: 2020-02-24
First Post: 2011-02-02
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myelogenous Leukemia View
None AML View
None High-Risk Myelodysplastic Syndrome View
None MDS View
None Relapsed View
None Refractory View
None Clofarabine View
None Clofarex View
None Clolar View
None Idarubicin View
None Idamycin View
None Cytarabine View
None Ara-C View
None Cytosar View
None DepoCyt View
None Cytosine Arabinosine Hydrochloride View